4//SEC Filing
DRISCOLL JOSEPH 4
Accession 0001104659-22-127961
CIK 0001711933other
Filed
Dec 15, 7:00 PM ET
Accepted
Dec 16, 5:59 PM ET
Size
14.2 KB
Accession
0001104659-22-127961
Insider Transaction Report
Form 4
DRISCOLL JOSEPH
Chief Financial Officer
Transactions
- Sale
Common Stock
2022-12-14$12.67/sh−10,039$127,187→ 12,500 total - Exercise/Conversion
Employee Stock Option (Right to Buy
2022-12-14−14,574→ 108,712 totalExercise: $0.44Exp: 2029-05-02→ Common Stock (14,574 underlying) - Exercise/Conversion
Common Stock
2022-12-14$0.44/sh+14,574$6,413→ 27,074 total - Sale
Common Stock
2022-12-14$12.46/sh−14,574$181,519→ 12,500 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2022-12-14−10,039→ 123,466 totalExercise: $0.44Exp: 2029-05-02→ Common Stock (10,039 underlying) - Exercise/Conversion
Common Stock
2022-12-14$0.44/sh+10,039$4,417→ 22,539 total
Footnotes (3)
- [F1]Column 4 reflects a weighted average price. Shares sold in multiple transactions at prices ranging from $12.60 - $12.80. Reporting person undertakes to provide issuer, securityholder of issuer or SEC staff, upon request, information regarding number of shares sold at each separate price within ranges set forth herein.
- [F2]Column 4 reflects a weighted average price. Shares sold in multiple transactions at prices ranging from $12.40 - $12.615. Reporting person undertakes to provide issuer, securityholder of issuer or SEC staff, upon request, information regarding number of shares sold at each separate price within ranges set forth herein.
- [F3]Such performance-based option shares were issued in 2019. In 2020, the options vested as performance conditions were determined to have been achieved.
Documents
Issuer
Akoya Biosciences, Inc.
CIK 0001711933
Entity typeother
Related Parties
1- filerCIK 0001392297
Filing Metadata
- Form type
- 4
- Filed
- Dec 15, 7:00 PM ET
- Accepted
- Dec 16, 5:59 PM ET
- Size
- 14.2 KB